New at Organix

Events

• Organix will be attending MassBio: Accelerating Drug Development on March 6, 2012 at Bentley University, LaCava Conference Center, Waltham, MA. Come and learn how Organix can assist your company with its Drug Discovery and Development Programs. See you there! https://checkout.massbio.org/events/calendar/


• Organix will be Exhibiting at the BioInternational Convention in Boston, June 18-21, 2012. Please stop by and discover the possibilities open to your company when it partners with Organix for early stage drug development. Let Organix help move your project in the right direction! http://convention.bio.org/

Testimonials

• “We have worked with Organix on a number of projects over several years, many of which involved very challenging chemistry. The high level of technical expertise of their scientists coupled with excellent communication really helped to make these projects a success. I have enjoyed working with Organix and would be happy to do so again in the future.” Dr. Michael Block, AstraZeneca


• “Organix has provided excellent service for SynDevRx medicinal chemistry discovery program over the past two years. Program management and communication have been outstanding. Transparency on technical as well as financial issues has been exceptional. I have enjoyed working with Organix and highly recommend their chemical synthesis services”. Dr. John Petersen, SynDevRx

News

• Navidea signs option agreement to license Parkinson’s imaging agent from Alseres. Altropane is a radiopharmaceutical used with Single-Photon Emission Computed Tomography (SPECT) imaging to identify the status of areas of the brains in patients suspected of having Parkinson’s disease, a nervous system disorder that leads to shaking known as tremors and difficulty in movement. The imaging agent works by binding to the dopamine transporter on nerve cells in the brain. Altropane was invented by a collaboration of scientists at Organix, Harvard Medical School, Massachusetts General Hospital, and Northeastern University, and licensed to Alseres. http://www.medcitynews.com/2012/01/navidea


• Boston Business Journal interviews Dr. Meltzer, CEO of Organix, on the state of CROs in the Boston area. http://www.bizjournals.com/boston/


• Galenea and Organix Announce Exclusive License Agreement for 5-HT2C Agonists for the Treatment of Obesity. http://www.biospace.com/news_story

New Publications

• The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes. Purushotham, M.; Sheri, A.; Pham-Huu, D-P.; Madras, B. K.; Janowsky, A.; Meltzer, P.C. Bioorg. & Med. Chem. Lett., 2011, 21, 48.


• The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects, Kinsey, S. G.; Mahadevan, A.; Zhao, B.; Sun, H.; Naidu, P. S.; Razdan, R. K.; Selley, D. E.; Imad Damaj, M.; Lichtman, A. H. Neuropharmacology 2011, 60, 244.


• Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB1 receptor antagonist, Wiley, J. L.; Breivogel, C. S.; Mahadevan, A.; Pertwee, R. G.; Cascio, M. G.; Bolognini, D.; Huffman, J. W.; Walentiny, M. D.; Vann, R. E.; Razdan, R. K.; Martin, B. R.; Eur. J. Pharmacol. 2011, 651, 96.

Back to Top